USD 0.62
(-18.09%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | -100.0% |
2020 | 558.66 Thousand USD | 20.73% |
2019 | 462.75 Thousand USD | -2.9% |
2018 | 476.55 Thousand USD | 590.46% |
2017 | 69.02 Thousand USD | -75.79% |
2016 | 285.05 Thousand USD | -56.64% |
2015 | 657.37 Thousand USD | 248875.32% |
2014 | 264.03 USD | 65.45% |
2013 | 159.58 USD | -99.94% |
2012 | 254.61 Thousand USD | -73.37% |
2011 | 956.15 Thousand USD | 523.71% |
2010 | 153.3 Thousand USD | 91.4% |
2009 | 80.09 Thousand USD | 1481.3% |
2008 | 5065.00 USD | -91.12% |
2007 | 57.04 Thousand USD | -54.53% |
2006 | 125.45 Thousand USD | -53.52% |
2005 | 269.92 Thousand USD | -17.07% |
2004 | 325.47 Thousand USD | 2.25% |
2003 | 318.3 Thousand USD | -17.31% |
2002 | 384.93 Thousand USD | 2.32% |
2001 | 376.22 Thousand USD | -6.42% |
2000 | 402.01 Thousand USD | 0.5% |
1999 | 400 Thousand USD | 300.0% |
1998 | 100 Thousand USD | -75.0% |
1997 | 400 Thousand USD | 33.33% |
1996 | 300 Thousand USD | 200.0% |
1995 | 100 Thousand USD | 0.0% |
1994 | 100 Thousand USD | -90.0% |
1993 | 1 Million USD | 150.0% |
1992 | 400 Thousand USD | 300.0% |
1991 | 100 Thousand USD | 0.0% |
1990 | 100 Thousand USD | 0.0% |
1989 | 100 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q3 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2021 Q1 | - USD | -100.0% |
2021 Q2 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 FY | - USD | -100.0% |
2021 Q4 | - USD | 0.0% |
2020 Q4 | 28.56 USD | 100.0% |
2020 FY | 558.66 Thousand USD | 20.73% |
2020 Q3 | -950.93 Thousand USD | -318430.18% |
2020 Q2 | 298.73 USD | 741.34% |
2020 Q1 | 35.51 USD | -53.67% |
2019 FY | 462.75 Thousand USD | -2.9% |
2019 Q1 | 126.41 USD | -29.58% |
2019 Q2 | 150.77 USD | 19.27% |
2019 Q3 | 108.94 USD | -27.75% |
2019 Q4 | 76.63 USD | -29.65% |
2018 Q2 | 114.27 USD | -99.9% |
2018 Q1 | 113.89 Thousand USD | 219885.03% |
2018 Q3 | 86.46 USD | -24.34% |
2018 FY | 476.55 Thousand USD | 590.46% |
2018 Q4 | 179.51 USD | 107.63% |
2017 Q2 | 17.18 USD | -0.48% |
2017 FY | 69.02 Thousand USD | -75.79% |
2017 Q4 | -51.82 USD | -398.02% |
2017 Q1 | 17.26 USD | -82.97% |
2017 Q3 | 17.39 USD | 1.25% |
2016 FY | 285.05 Thousand USD | -56.64% |
2016 Q1 | 20.98 USD | -100.0% |
2016 Q4 | 101.33 USD | -22.04% |
2016 Q3 | 129.98 USD | 296.57% |
2016 Q2 | 32.78 USD | 56.25% |
2015 Q4 | 657.37 Thousand USD | 168794.7% |
2015 FY | 657.37 Thousand USD | 248875.32% |
2015 Q1 | 136.84 USD | 101.77% |
2015 Q3 | 389.22 USD | 96.96% |
2015 Q2 | 197.62 USD | 44.42% |
2014 FY | 264.03 USD | 65.45% |
2014 Q2 | 67.16 USD | -40.64% |
2014 Q3 | 15.91 USD | -76.3% |
2014 Q4 | 67.82 USD | 326.15% |
2014 Q1 | 113.14 USD | 632.32% |
2013 Q2 | 15.41 USD | 2.7% |
2013 FY | 159.58 USD | -99.94% |
2013 Q4 | 15.45 USD | -86.41% |
2013 Q3 | 113.73 USD | 638.25% |
2013 Q1 | 15.00 USD | -99.99% |
2012 Q1 | 5024.00 USD | -97.08% |
2012 Q4 | 108.04 Thousand USD | 208.69% |
2012 Q3 | 35 Thousand USD | -67.15% |
2012 Q2 | 106.54 Thousand USD | 2020.68% |
2012 FY | 254.61 Thousand USD | -73.37% |
2011 Q1 | 662.81 Thousand USD | 972.52% |
2011 Q4 | 172.11 Thousand USD | 122.37% |
2011 Q2 | 43.81 Thousand USD | -93.39% |
2011 FY | 956.15 Thousand USD | 523.71% |
2011 Q3 | 77.4 Thousand USD | 76.66% |
2010 Q2 | 30.6 Thousand USD | 2.0% |
2010 Q1 | 30 Thousand USD | 0.0% |
2010 Q3 | 30.9 Thousand USD | 0.98% |
2010 Q4 | 61.8 Thousand USD | 100.0% |
2010 FY | 153.3 Thousand USD | 91.4% |
2009 Q4 | 30 Thousand USD | -1.48% |
2009 Q3 | 30.45 Thousand USD | 55.02% |
2009 Q2 | 19.64 Thousand USD | 0.0% |
2009 FY | 80.09 Thousand USD | 1481.3% |
2009 Q1 | - USD | 0.0% |
2008 FY | 5065.00 USD | -91.12% |
2008 Q4 | - USD | -100.0% |
2008 Q1 | 1530.00 USD | -69.88% |
2008 Q2 | - USD | -100.0% |
2008 Q3 | 3535.00 USD | 0.0% |
2007 Q1 | 13.86 Thousand USD | -27.37% |
2007 FY | 57.04 Thousand USD | -54.53% |
2007 Q4 | 5079.00 USD | -21.24% |
2007 Q3 | 6449.00 USD | -73.91% |
2007 Q2 | 24.72 Thousand USD | 78.34% |
2006 Q2 | 36.81 Thousand USD | 23.35% |
2006 Q1 | 29.84 Thousand USD | -35.85% |
2006 FY | 125.45 Thousand USD | -53.52% |
2006 Q4 | 19.08 Thousand USD | -51.93% |
2006 Q3 | 39.7 Thousand USD | 7.86% |
2005 Q3 | 38.1 Thousand USD | -65.29% |
2005 Q2 | 109.78 Thousand USD | 45.4% |
2005 Q1 | 75.5 Thousand USD | 5.61% |
2005 FY | 269.92 Thousand USD | -17.07% |
2005 Q4 | 46.53 Thousand USD | 22.12% |
2004 Q4 | 71.49 Thousand USD | -12.31% |
2004 Q3 | 81.53 Thousand USD | -17.82% |
2004 Q2 | 99.21 Thousand USD | 35.47% |
2004 Q1 | 73.23 Thousand USD | -39.37% |
2004 FY | 325.47 Thousand USD | 2.25% |
2003 Q2 | 82.68 Thousand USD | 56.15% |
2003 Q1 | 52.95 Thousand USD | 551.03% |
2003 Q3 | 61.87 Thousand USD | -25.17% |
2003 FY | 318.3 Thousand USD | -17.31% |
2003 Q4 | 120.78 Thousand USD | 95.2% |
2002 Q1 | 176.24 Thousand USD | 200.73% |
2002 Q4 | 8134.00 USD | -92.43% |
2002 Q3 | 107.51 Thousand USD | 15.54% |
2002 Q2 | 93.05 Thousand USD | -47.2% |
2002 FY | 384.93 Thousand USD | 2.32% |
2001 Q4 | -174.96 Thousand USD | -181.95% |
2001 Q1 | 249.8 Thousand USD | -37.86% |
2001 Q2 | 87.88 Thousand USD | -64.82% |
2001 Q3 | 213.49 Thousand USD | 142.91% |
2001 FY | 376.22 Thousand USD | -6.42% |
2000 Q2 | 78.89 Thousand USD | -21.1% |
2000 FY | 402.01 Thousand USD | 0.5% |
2000 Q1 | 100 Thousand USD | -66.67% |
2000 Q4 | 402.01 Thousand USD | 40200900.0% |
2000 Q3 | 1.00 USD | -100.0% |
1999 Q2 | 100 Thousand USD | 0.0% |
1999 Q3 | 100 Thousand USD | 0.0% |
1999 Q4 | 300 Thousand USD | 200.0% |
1999 FY | 400 Thousand USD | 300.0% |
1999 Q1 | 100 Thousand USD | 0.0% |
1998 FY | 100 Thousand USD | -75.0% |
1998 Q1 | 100 Thousand USD | -66.67% |
1998 Q2 | 100 Thousand USD | 0.0% |
1998 Q3 | 100 Thousand USD | 0.0% |
1998 Q4 | - USD | -100.0% |
1997 Q4 | 300 Thousand USD | 200.0% |
1997 Q2 | 100 Thousand USD | 0.0% |
1997 Q3 | 100 Thousand USD | 0.0% |
1997 FY | 400 Thousand USD | 33.33% |
1997 Q1 | 100 Thousand USD | 0.0% |
1996 Q3 | 100 Thousand USD | 0.0% |
1996 Q1 | 100 Thousand USD | 0.0% |
1996 FY | 300 Thousand USD | 200.0% |
1996 Q4 | 100 Thousand USD | 0.0% |
1996 Q2 | 100 Thousand USD | 0.0% |
1995 Q3 | 100 Thousand USD | 0.0% |
1995 Q1 | 100 Thousand USD | 0.0% |
1995 Q2 | 100 Thousand USD | 0.0% |
1995 Q4 | - USD | -100.0% |
1995 FY | 100 Thousand USD | 0.0% |
1994 Q2 | 300 Thousand USD | 50.0% |
1994 Q3 | 100 Thousand USD | -66.67% |
1994 Q4 | - USD | -100.0% |
1994 FY | 100 Thousand USD | -90.0% |
1994 Q1 | 200 Thousand USD | -50.0% |
1993 Q1 | 200 Thousand USD | 100.0% |
1993 Q4 | 400 Thousand USD | 100.0% |
1993 Q2 | 100 Thousand USD | -50.0% |
1993 FY | 1 Million USD | 150.0% |
1993 Q3 | 200 Thousand USD | 100.0% |
1992 Q4 | 100 Thousand USD | -50.0% |
1992 Q1 | 100 Thousand USD | 0.0% |
1992 Q2 | 100 Thousand USD | 0.0% |
1992 FY | 400 Thousand USD | 300.0% |
1992 Q3 | 200 Thousand USD | 100.0% |
1991 Q2 | 100 Thousand USD | 0.0% |
1991 Q3 | 100 Thousand USD | 0.0% |
1991 Q4 | - USD | -100.0% |
1991 Q1 | 100 Thousand USD | 0.0% |
1991 FY | 100 Thousand USD | 0.0% |
1990 FY | 100 Thousand USD | 0.0% |
1990 Q4 | - USD | -100.0% |
1990 Q3 | 100 Thousand USD | 0.0% |
1990 Q2 | 100 Thousand USD | 0.0% |
1990 Q1 | 100 Thousand USD | 0.0% |
1989 Q3 | 100 Thousand USD | 0.0% |
1989 Q4 | - USD | -100.0% |
1989 Q2 | 100 Thousand USD | 0.0% |
1989 Q1 | 100 Thousand USD | 0.0% |
1989 FY | 100 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AIM ImmunoTech Inc. | 202 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | - USD | NaN% |
Armata Pharmaceuticals, Inc. | 4.52 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | 81 Thousand USD | 100.0% |
Azitra, Inc. | 686 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | - USD | NaN% |
Calidi Biotherapeutics, Inc. | - USD | NaN% |
iBio, Inc. | 225 Thousand USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 100.0% |
MAIA Biotechnology, Inc. | - USD | NaN% |
Matinas BioPharma Holdings, Inc. | 1.09 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 100.0% |
NanoViricides, Inc. | - USD | NaN% |
Oragenics, Inc. | 37.65 Thousand USD | 100.0% |
BiomX Inc. | -357 Thousand USD | 100.0% |
BiomX Inc. | -357 Thousand USD | 100.0% |
Protalix BioTherapeutics, Inc. | 65.49 Million USD | 100.0% |
Palatin Technologies, Inc. | 4.49 Million USD | 100.0% |
Scorpius Holdings, Inc. | 6.99 Million USD | 100.0% |